Jacobs Levy Equity Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Jacobs Levy Equity Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-250,724	Closed	-$5.09M	–	1121
2017 Q3	$5.09M	Buy	250,724 +128,459	+105%	+$2.46M	0.1%	255
2017 Q2	$1.97M	Sell	122,265 -60,450	-33%	-$893K	0.04%	430
2017 Q1	$2.31M	Sell	182,715 -2,300	-1%	-$27.8K	0.05%	393
2016 Q4	$2.45M	Sell	185,015 -34,815	-16%	-$595K	0.05%	381
2016 Q3	$5.21M	Buy	+219,830	New	+$5.91M	0.09%	262
2014 Q3	–	Sell	-69,721	Closed	-$2.09M	–	959
2014 Q2	$2.09M	Buy	69,721 +47,220	+210%	+$1.27M	0.03%	396
2014 Q1	$594K	Sell	22,501 -82,608	-79%	-$2.06M	0.01%	638
2013 Q4	$2.64M	Buy	105,109 +57,310	+120%	+$1.28M	0.04%	384
2013 Q3	$978K	Buy	+47,799	New	+$987K	0.02%	537

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCW Group Los Angeles, California $13.3B AUM 34.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management's IPXL Position: Q4 2017 in Review

Jacobs Levy Equity Management sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 250,724 shares — an estimated $5.09M sold.

Jacobs Levy Equity Management first reported a position in IPXL in Q3 2013 and held it in 9 quarters. The position peaked at $5.21M in Q3 2016. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

Jacobs Levy Equity Management reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
Jacobs Levy Equity Management sold 250,724 Impax Laboratories, Inc. shares in Q4 2017, an estimated $5.09M.
Jacobs Levy Equity Management first reported a position in Impax Laboratories, Inc. in Q3 2013 and held it in 9 quarters.
Jacobs Levy Equity Management's Impax Laboratories, Inc. position peaked at $5.21M in Q3 2016.
200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2017, filed 13 Feb 2018.